Pandion announces first subject dosed in phase 1 trial of PT101, an IL-2 mutein Fc fusion therapy for autoimmune disease
“PT101, the lead program in our pipeline of modular protein therapeutics, has the potential to transform the standard of care for patients with a wide array of autoimmune
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.